Promising drug targets rare skin cancer in chinese patients

NCT ID NCT06285370

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests a drug called mogamulizumab in 23 Chinese adults with a rare type of skin cancer (mycosis fungoides or Sézary syndrome) that has not responded to prior treatment. The goal is to see if the drug can shrink or eliminate the cancer. Participants receive the drug intravenously, and doctors monitor their response and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • First Affiliated Hospital of Zhengzhou University

    Henan, Zhengzhou, 450052, China

  • Peking University First Hospital, Department of Dermatology and Venereology

    Beijing, Beijing Municipality, 100034, China

  • Sun Yat-sen University Cancer Center, Department of Medical Oncology

    Guangzhou, Guangdong, 510060, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, 010000, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110002, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610044, China

  • ZheJiang Cancer Hospital

    Hangzhou, Zhejiang, 310005, China

Conditions

Explore the condition pages connected to this study.